Clinical Trials

Clinical Trials



Fostamatinib - Immune Thrombocytopenic Purpura:

A phase 3 program comprising two multi-center, randomized, double-blind, placebo-controlled clinical studies of fostamatinib disodium in the treatment of persistent/chronic immune thrombocytopenic purpura (ITP). The purpose of these studies is to determine whether fostamatinib is safe and effective in the treatment of persistent/chronic ITP.

Phase 3 - ITP (047) Phase 3 - ITP (048)

Fostamatinib - AIHA

A phase 2, open-label (active only), multi-center clinical study of fostamatinib disodium in the treatment of warm antibody autoimmune hemolytic anemia (AIHA). The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of AIHA.

Phase 2 - AIHA

Fostamatinib - IgA Nephropathy:

A phase 2, multi-center, randomized, double-blind, ascending-dose, placebo-controlled clinical study of fostamatinib disodium in the treatment of IgA Nephropathy (IgAN). The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgAN.

Phase 2 - IgA Nephropathy

R348 - Dry Eye in Ocular GvHD:

A phase 2, two-center, randomized, double-masked, placebo-controlled clinical study of R348 in the treatment of keratoconjunctivitis sicca in chronic ocular graft versus host disease (GvHD). The purpose of this study is to investigate the safety and efficacy of 0.2% and 0.5% R348 ophthalmic solutions for the treatment of patients with this disease, as assessed by corneal (fluorescein) staining (a measure of inflammation and damage), and overall tolerability.

Phase 2 - Dry Eye in Ocular GvHD